Literature DB >> 8486015

Changing patterns of aerosol deposition during methacholine bronchoprovocation.

T G O'Riordan1, L Walser, G C Smaldone.   

Abstract

During bronchoprovocation testing with methacholine, induced changes in airway geometry are known to affect sites of drug deposition. However, it is not known if changes in these sites determine measured responsiveness. We assessed the importance of sites of deposition as determinants of reactivity by comparing particle behavior in two subject groups with and without hyperresponsiveness. By administering radiolabeled aerosols of similar aerodynamic characteristics to methacholine aerosol, we measured the deposition pattern in terms of the specific central to peripheral ratio (sC/P) before and after methacholine inhalation (sC/P1 and sC/P2, respectively) and thereby quantified the changes in deposition sites that occur during the course of a typical bronchoprovocation test. Subjects whose FEV1 decreased by 20 percent or greater were classified as methacholine responsive (MR; nine subjects), and the remainder were classified as non-methacholine responsive (NMR; seven subjects). The two groups had similar baseline FEV1 percent predicted (FEV1 percent) and initial deposition patterns (sC/P1) with particles depositing primarily in peripheral airways (mean +/- SE; sC/P1 1.43 +/- 0.070 and 1.39 +/- 0.65, MR and NMR, respectively, p = NS). Following methacholine inhalation, the deposition pattern changes markedly for all subjects with particles depositing primarily in central airways (sC/P2 2.58 +/- 0.24, p = 0.001, and 2.15 +/- 0.22, p = 0.001 from baseline, p = NS between groups) By definition, the MR subjects had a significantly greater change in FEV1 than the NMR subjects. Preferential deposition in central airways occurs in all subjects during bronchoprovocation testing and does not significantly determine methacholine responsiveness.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486015     DOI: 10.1378/chest.103.5.1385

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  7 in total

Review 1.  Aerosol deposition in health and disease.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-06       Impact factor: 2.849

2.  Regional Ventilation Is the Main Determinant of Alveolar Deposition of Coarse Particles in the Supine Healthy Human Lung During Tidal Breathing.

Authors:  Rui Carlos Sá; Kirby L Zeman; William D Bennett; G Kim Prisk; Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2017-03-09       Impact factor: 2.849

3.  Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size.

Authors:  J E Esposito-Festen; P Zanen; H A W M Tiddens; J-W J Lammers
Journal:  Br J Clin Pharmacol       Date:  2007-04-18       Impact factor: 4.335

4.  Effect of inhaled dust mite allergen on regional particle deposition and mucociliary clearance in allergic asthmatics.

Authors:  W D Bennett; M Herbst; N E Alexis; K L Zeman; J Wu; M L Hernandez; D B Peden
Journal:  Clin Exp Allergy       Date:  2011-07-05       Impact factor: 5.018

5.  Ventilation heterogeneity is a major determinant of airway hyperresponsiveness in asthma, independent of airway inflammation.

Authors:  Sue R Downie; Cheryl M Salome; Sylvia Verbanck; Bruce Thompson; Norbert Berend; Gregory G King
Journal:  Thorax       Date:  2007-02-20       Impact factor: 9.139

6.  Effect of inhaled endotoxin on regional particle deposition in patients with mild asthma.

Authors:  William D Bennett; Margaret Herbst; Kirby L Zeman; Jihong Wu; Michelle L Hernandez; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2012-10-25       Impact factor: 10.793

7.  Particle deposition in a child respiratory tract model: in vivo regional deposition of fine and ultrafine aerosols in baboons.

Authors:  Iolanda Albuquerque-Silva; Laurent Vecellio; Marc Durand; John Avet; Déborah Le Pennec; Michèle de Monte; Jérôme Montharu; Patrice Diot; Michèle Cottier; Francis Dubois; Jérémie Pourchez
Journal:  PLoS One       Date:  2014-04-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.